pharma · Colorectal Cancer · Lymphoma, Extranodal NK-T-Cell
Samsung Bioepis
Samsung Bioepis NL B.V.
Samsung Bioepis is a pharma organization headquartered in KR. Primary therapeutic focus areas include Colorectal Cancer, Lymphoma, Extranodal NK-T-Cell, Cancer of Stomach, Dyspepsia, Depression. NovaPharmaNews links 24 c
Yeonsu-gu, Incheon 21987, KR HQ
2012 Founded
1,589 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Yeonsu-gu, Incheon 21987, KR
- Founded
- 2012
- Employees
- 1,589
- Programs
- 24
- Drugs
- 34
- Patents
- 0
SB11 (Proposed ranibizumab biosimilar)
Phase 3 · small molecule · Age-Related Macular Degeneration
SB11 (Proposed ranibizumab biosimilar) for Age-Related Macular Degeneration is a Phase 3 program (small_molecule) at Samsung Bioepis NL B.V. with 1 ClinicalTrials.gov record(s).
Internal code SB11-G31-AMD
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Samsung Bioepis NL B.V.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Age-Related Macular Degeneration
- Status
- completed
- Trials
- 1